Cite
ESTIMATION OF LONG‐TERM SURVIVAL WITH TAFASITAMAB + LENALIDOMIDE (LEN) IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL)
MLA
Salles, G., et al. “Estimation of Long‐Term Survival with Tafasitamab + Lenalidomide (Len) in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma (R/R Dlbcl).” Hematological Oncology, vol. 39, June 2021, pp. 1–3. EBSCOhost, https://doi.org/10.1002/hon.89_2880.
APA
Salles, G., Goswami, B., Bagnardi, V., Dey, D., Winderlich, M., Ambarkhane, S., Huang, D., & Nowakowski, G. S. (2021). Estimation of Long‐Term Survival with Tafasitamab + Lenalidomide (Len) in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma (R/R Dlbcl). Hematological Oncology, 39, 1–3. https://doi.org/10.1002/hon.89_2880
Chicago
Salles, G, B Goswami, V Bagnardi, D Dey, M Winderlich, S Ambarkhane, D Huang, and G. S Nowakowski. 2021. “Estimation of Long‐Term Survival with Tafasitamab + Lenalidomide (Len) in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma (R/R Dlbcl).” Hematological Oncology 39 (June): 1–3. doi:10.1002/hon.89_2880.